Proactive Investors
20 Aug 2026, 09:16 UTC · 6w ago
Shield Therapeutics jumps 11% as losses narrow and profitability target held
Impact · against what's priced in
Shield Therapeutics provides a positive catalyst through significant loss narrowing and distribution expansion, though Medicaid price erosion creates a headwind. Rome Resources offers speculative upside based on new exploration zones.
- STX+0.50
No priced-in read yet
- In context
The 42% revenue increase to $30.4 million and the narrowing of losses to $2.3 million support the 2026 profitability target. Access to 400 additional clinics via a new GPO contract provides a concrete growth lever, though New York Medicaid rules have lowered the average net selling price to $199.
Read from the article alone
